Sugi Predict

Sugi Predict / Compounds / SCHEMBL15831715

SCHEMBL15831715

SCHEMBL15831715

Clc1nc(Cl)c2c(n1)CCCCC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 2/20 0.46
▸ NSD2 O96028 1/20 0.46
▸ ACHE P22303 11/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ BPTF Q12830 1/20 0.41
▸ BCHE P06276 7/20 0.38
▸ GRIN1 Q05586 4/20 0.38
▸ GRIN2A Q12879 4/20 0.38
▸ KDM4E B2RXH2 2/20 0.36
▸ CHRM1 P11229 2/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ NOS3 P29474 1/20 0.35
▸ NOS1 P29475 1/20 0.35
▸ NOS2 P35228 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ CACNB4 O00305 1/20 0.35
▸ CACNA1A O00555 1/20 0.35
▸ SLC22A2 O15244 1/20 0.35
▸ SLC22A1 O15245 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31095398 1.00 MAPK1 (0.46) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL23816987 1.00 MAPK1 (0.46) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL16136206 1.00 MAPK1 (0.46) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL1819184 0.98 MAPK1 (0.47) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL29466623 0.98 MAPK1 (0.47) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL633261 0.93 ACHE (0.43) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL30777931 0.93 ACHE (0.43) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL13056600 0.78 MAPK1 (0.43) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL24954180 0.78 KDM4E (0.57) MAPK1NSD2ACHEMEN1KMT2A
SCHEMBL11288061 0.78 ACHE (0.50) MAPK1ACHEMEN1KMT2ABPTF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119060060-A Imidazole-containing ALK2 kinase inhibitors 拜奥克里斯特制药公司 2024-12-03 — — CN disclosed
US-20240376117-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2024-11-14 — — US disclosed
CN-110913855-B Imidazole-containing ALK2 kinase inhibitors 拜奥克里斯特制药公司 2024-09-03 — — CN disclosed
US-12054492-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2024-08-06 — — US disclosed
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-08-31 — — US disclosed
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-08-31 — — US disclosed
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-08-31 — — US disclosed
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2023-05-30 — — US disclosed
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2023-05-30 — — US disclosed
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase BIOCRYST PHARMACEUTICALS, INC. (US) 2023-05-30 — — US disclosed
US-20220332723-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2022-10-20 — — US disclosed
WO-2021180952-A9 FUSED PYRIMIDINE COMPOUNDS AS KCC2 MODULATORS ASTRAZENECA AB (SE) 2021-12-16 — — WO disclosed
WO-2021180952-A1 FUSED PYRIMIDINE COMPOUNDS AS KCC2 ASTRAZENECA AB (SE) 2021-09-16 — — WO disclosed
EP-3638229-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE Biocryst Pharmaceuticals, Inc. (US) 2020-04-22 — — EP disclosed
CN-110913855-A Imidazole-containing ALK2 kinase inhibitors 拜奥克里斯特制药公司 2020-03-24 — — CN disclosed
WO-2018232094-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE BIOCRYST PHARMACEUTICALS, INC. (US) 2018-12-20 — — WO disclosed
US-9499519-B2 Fused pyrimidine compounds and use thereof MEDIVATION TECHNOLOGIES, INC. (US) 2016-11-22 — — US disclosed
US-9422267-B2 Fused pyrimidine compounds and use thereof MEDIVATION TECHNOLOGIES, INC. (US) 2016-08-23 — — US disclosed
US-20160068513-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF MEDIVATION TECHNOLOGIES, INC. (US) 2016-03-10 — — US disclosed
US-20140179668-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF MEDIVATION TECHNOLOGIES, INC. (US) 2014-06-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160068513-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF IGF1R, FGFR3, FGFR1 MAPK1 620/4885NSD2 3425/4885ACHE 4706/4885
US-20230271975-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A MAPK1 149/4885NSD2 2755/4885ACHE 4702/4885
US-11661426-B2 Imidazole-containing inhibitors of ALK2 kinase ALK, ACVR2B, ACVR2A MAPK1 149/4885NSD2 2755/4885ACHE 4702/4885
US-20240376117-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A MAPK1 149/4885NSD2 2755/4885ACHE 4702/4885
US-20220332723-A1 IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE ALK, ACVR2B, ACVR2A MAPK1 149/4885NSD2 2755/4885ACHE 4702/4885
US-12054492-B2 Imidazole-containing inhibitors of ALK2 kinase ALK, ACVR2B, ACVR2A MAPK1 149/4885NSD2 2755/4885ACHE 4702/4885
US-20140179668-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF IGF1R, IPMK, IP6K2 MAPK1 437/4885NSD2 2551/4885ACHE 4211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.